New drug combo aims to keep High-Risk nasopharyngeal cancer at bay
NCT ID NCT06277050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding toripalimab (an immunotherapy) to capecitabine (a chemotherapy pill) as maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. The study enrolls 264 adults aged 18-70 who have completed initial chemotherapy and radiation. The goal is to see if the combination delays cancer progression or death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital
RECRUITINGNanchang, None Selected, 330029, China
-
First Affiliated hospital of Gannan Medical University
RECRUITINGGuangzhou, Jiangxi, 341000, China
-
Ganzhou Cancer Hospital
NOT_YET_RECRUITINGGanzhou, Jiangxi, 341000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment